Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- EA Pharma Licenses SHPT Treatment to China Firm
June 13, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Ethical Drug Sales Jump 7.6% in April on Price Revision: Crecon
June 12, 2018
- Parkinson’s Drug Azilect Now Available in Japan: Takeda
June 12, 2018
- Vortioxetine Showed Positive Results in Japan PIII with MDD Patients: Takeda/Lundbeck
June 12, 2018
- Biogen Enters Exclusive Option Agreement for Acute Stroke Treatment with Japanese Biotech
June 12, 2018
- Astellas Launches Tablet Formulations of Xtandi
June 12, 2018
- Takeda Inks US$7.5 billion Term Loan Credit to Refinance M&A Bridge
June 11, 2018
- FY2017 Earnings Roundup - 4: Japan Makers Struggling to Recoup R&D Investments, New Value-Generating Model Is a Must
June 8, 2018
- Bayer Establishes Asia’s 1st “CoLaborator” in Kobe for Use by Startups
June 8, 2018
- FY2017 Earnings Roundup - 3: Top 3 Japan Generic Makers Pursuing Diversified Overseas Strategies
June 7, 2018
- Shionogi’s Single-Dose Flu Med Xofluza Heavily Promoted in March: Anterio
June 7, 2018
- Olmesartan Lawsuit Settlement in US Now Valid: Daiichi Sankyo
June 7, 2018
- Nobelpharma’s Rapalimus Now Available in Japan
June 7, 2018
- Pexidartinib Delivers Significant ORR in PIII: Daiichi Sankyo
June 6, 2018
- Takeda’s Founding Family-Backed Shareholders Demand Prior Vote for 1 Trillion Yen-Plus Deals
June 6, 2018
- AbbVie Japan Seeks Hidradenitis Suppurativa Nod for Humira
June 6, 2018
- Yakult Honsha Obtains Rights to Hematologic Cancer Agent from US Biopharma
June 6, 2018
- Rxulti Earns European Panel Nod for Schizophrenia: Otsuka/Lundbeck
June 5, 2018
- FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
June 5, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…